Trifork Group and Medartis report strong mid-2026 financial growth

Trifork Group AG reported its Q2 2026 interim results, showing an 11% growth in adjusted organic revenue and a 21% increase in adjusted EBITDA. The company attributed this performance to strong execution in its Products division and robust performance in Services. CEO Jørn Larsen noted that the company is transitioning toward a product-led model, with product revenue growing organically by 23% (excluding hardware) and contributing 50% of EBITDA over the last 12 months.

Medartis Holding AG reported H1 2026 results with organic sales growth of 17.0% in its core business, totaling CHF 160.8 million. The company achieved a core EBITDA margin of 18.0%. Growth was driven primarily by the US and EMEA regions, supported by new product introductions and the international rollout of the TOUCH prosthesis. CEO Matthias Schupp highlighted progress in Latin America and the US distribution network, noting that the TOUCH prosthesis has received a dedicated reimbursement code in Australia.